- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Hikma Reaches Rituximab Licensing Agreement With Celltrion
Hikma Pharmaceuticals Plc. announced yesterday that it has reached a licensing agreement with Republic of Korea-based Celltrion for its rituximab biosimilar, Truxima, referenced on MabThera.
Hikma Pharmaceuticals Plc. announced yesterday that it has reached a licensing agreement with Republic of Korea-based Celltrion for its rituximab biosimilar, Truxima, referenced on MabThera. Hikma, based in Jordan, now has exclusive rights from Celltrion to market 3 biosimilar products, rituximab (Truxima), infliximab (Remsima), and trastuzumab (Herzuma) in all of the Middle East and North African (MENA) markets.
Truxima was the first biosimilar anticancer therapeutic to hit the European market in February 2017. Truxima, like the reference rituximab, which is sold in the European Union as MabThera (and as Rituxan in the United States), is used to treat patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and microscopic polyangiitis, among other indications.
Mazen Darwazah, vice chairman and CEO of MENA and Emerging Markets said, “We are pleased to be adding Truxima to our biosimilar and oncology portfolio, building on the success of our partners with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients’ access to high-quality, affordable medicines.”
The Jordan-based company boasts a product portfolio of over 700 products across key therapeutic areas. Hikma makes and markets branded and non-branded generic and injectable drugs in more than 50 different countries. Yet the company has been hit by higher pricing pressures in the generic industry, and has lowered revenue forecasts 3 times this year alone.
Hikma is also currently in a dispute with the FDA over plans to launch a generic copy of GlaxoSmithKline’s popular drug Advair in the United States. The root of the issue is the team’s clinical endpoint study, according to Hikma, which says it “firmly” disagrees with the FDA’s concerns. With Hikma in a potentially lengthy delay, Novartis’ Sandoz could be the uncontested first-place winner in the race to bring a generic of the respiratory blockbuster to the market.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
